The Generalized Anxiety Disorder (GAD) is defined as the basic anxiety disorder, which may reflect ‎the fundamental process of all emotional disorders and significant degree of functional ‎impairment ([@B1]). GAD is hyper-reactivity and a fear of negative emotional shifts and ‎unmanageable worry about preventing these perceptive contrasts ([@B2]). The symptoms are difficult ‎to control and last for more than six months. GAD is associated with three or more of diagnostic ‎items from DSM-IV (Diagnostic and Statistical manual of Mental illnesses-4th edition) including: ‎Feeling keyed up or on edge, easily getting fatigue, mind going blank, agitation, somatic tension ‎and sleep disturbances. Treatment choices include psychological therapies such as cognitive ‎behavioral therapy (CBT) as the main non-pharmacological therapy ([@B3]), acceptance and ‎commitment therapy ([@B4]), intolerance of uncertainty therapy and motivational interviewing ([@B5]) as ‎well as pharmacotherapy including Selective Serotonin Reuptake Inhibitors (SSRIs) ([@B6]), Benzodiazepines ([@B7]), Pregabalin ([@B8]) and ‎Gabapentin ([@B9]), Tricyclic Antidepressants (TCAs), Buspirone and Hydroxyzine ([@B6]). Reaction Time (RT) is defined as the time ‎elapsed between offering stimuli and the indication of comprehension by the subject ([@B10]). RT is ‎claimed to be the main dependent variable for analyzing perceptive models ([@B11]).

Response procedure is directly based on circumstances ([@B12]). Many factors may be responsible for ‎reaction time fluctuations, specially a great number of drugs and substances e.g., Caffeine ([@B13]), ‎alcohol ([@B14]), psychostimulants ([@B15]), sedative-hypnotic and anti-epileptic drugs ([@B16], [@B17]) and many ‎of cognitive side effects, which are raised by psychiatric pharmacotherapies ([@B18], [@B19]).

‎Passion flower symbolizes the passion of Jesus in Christian theology because of its unique ‎structure ([@B20]).

‎Traditionally its extract has been used as an herbal remedy for nervous anxiety ([@B21]) and ‎insomnia, tenderness, restlessness, irritability ([@B22]) and hysteria ([@B23]). Passion flower has been ‎reported to affect GAD ([@B24]). Most of these effects are believed to be related to benzoflavone, ‎which is the active constituent of the plant extract ([@B25]). We aimed to investigate the effects of ‎passion flower extract on perceptual processing toward threats via reaction time test since its ‎advantage on mental function did not receive specific reflections in previous studies.‎‎

Materials and Method
====================

***Research Participants***

Thirty outpatients entered this randomized double-blind placebo-controlled study (Ethical ‎approval number 7408 - by Ethics Committee at Islamic Azad University of Pharmaceutical ‎Sciences). The participants were included in the study from Roozbeh and Baharloo hospitals and ‎private psychiatric offices during 2010- 2012. Patients were diagnosed with Generalized Anxiety ‎Disorder (GAD) based on DSM-IV criteria and clinical interviews. Their family history was ‎considered as well. They were tested using Hamilton Anxiety Rating Scale Form A (HARS). ‎Hamilton Rating Scale for Depression (HRSD) was utilized to determine the patients' comorbid ‎depression. The Hamilton Scales were standardized for Iranian patients.

Patients between 18 to 24 years of age were included. In addition, sertraline consumption was ‎considered the best treatment for their current disease per decision of the psychiatrist. All patients ‎were initiated on Sertraline. The exclusion criteria were as follows: Having difficulty including ‎allergic reactions to sertraline or active ingredients of passion flower, renal or hepatic impairment, ‎age under 18, pregnancy and lactation, consuming Warfarin, Hexobarbital, Pantobarbital, ‎Levothyroxine or other thyroid medications, using alcohol or hallucinogens and history of ‎tachycardia. The patients with a history of kidney or liver dysfunction were excluded. An ‎informed consent was obtained from the patients prior to the initiation of the examination. ‎

***Medication***

The first-line treatment for GAD patients was 50 mg Sertraline tablet for both groups. Pasipy® Drop - Iran Darouk Co. was the standardized hydroalcoholic extract of passion flower as ‎an add-on therapy.

Placebo consisted of 20% aqueous solution of absolute edible alcohol and natural coloring ‎agents. The placebo mixture was filled in amber glass bottles with dropper identical to the drug ‎container.‎

***Assortment***

The participants were randomly assigned into two groups to receive either Sertraline + Pasipy (S-‎drug group), or Sertraline + placebo (S-placebo group) for one month. All patients were initiated on ‎Sertraline 50 mg/day; the dosage was increased to 100 mg/day after two weeks. Pasipy and its ‎placebo were given at 15 drops three times daily.‎

***Data Collection Tools***

The Reaction Time (RT) test was utilized as the standard computerized software. These process ‎measured psycho-neural responses toward visual and auditory stimuli. The input variables ‎were the number of correct responses, omission and substitution errors and the mean time of ‎correct responses (mean reaction time) ([@B26]). After receiving each of the visual or auditory stimuli, the participants were asked to hit the correct keys, which were designed on a computer ‎keyboard. The sign on each key was related to a specific visual or auditory threat in the tests. The ‎ stimuli were presented continuously on the screen during the test procedure. Correct responses ‎were made when the participants had chosen the key that was the same as the presented stimulus, ‎whereas choosing an incorrect answer was considered as a substitution error. When the patient ‎ignored a visual or auditory stimuli, the answer was recorded as an omission error. Reaction ‎time was the mean time of correct responses to stimuli in each of the visual or auditory tests. ‎Test items were measured at baseline and after one month of S-drug or S-placebo administration. ‎A questionnaire of adverse effects or possible drug interactions was filled at the end of the study.‎

***Statistical Analysis***

Demographic characteristics were compared between the two groups. The RT test outputs were analyzed once in comparison between S-drug and S-placebo groups ‎using independent sample t-test (inter-group comparison); then reaction time changes after one ‎month was determined in each group using a paired sample t-test (intra-group comparison). ‎Scores from the Hamilton anxiety scale form A (HAM-A) were compared between S-drug and S-‎placebo groups using an independent sample t-test. The aim was to reconfirm the positive effect ‎of passion flower on GAD and the possible improvement of the add-on therapy encountered with ‎the SSRI monotherapy. All the comparisons were performed utilizing SPSS software (PASW -- ‎statistics 18). A p-value of less than 0.05 was considered as the minimal level of statistical ‎significance in all measures.‎

Results
=======

Seventy patients were selected for the study; of whom, 24 were excluded as they did not meet our ‎criteria, and 16 did not follow the medication protocol because of low compliance and drug ‎incompatibility. The patients who met the inclusion criteria were randomized by permeated block ‎randomization ([Table 1](#T1){ref-type="table"}).‎

###### 

Demographic characteristics of patients in both groups

  Group                                          **Sertraline + drug**   **Sertraline + placebo**   **P-value**
  ---------------------------------------------- ----------------------- -------------------------- -------------
  Age(mean±SD [¶](#TFN1){ref-type="table-fn"})   29.07 ± 8.60            32.19 ± 11.43              0.410
  Gender (Percent)                               F: 85.7% - M: 14.3%     F: 87.5% - M: 12.5%        0.891
  Caffeine intake (mg/day)                       173.54 ± 99.17          130.46 ± 67.98             0.203

\*: Significant difference (P-value \< 0.05)

SD: Standard deviation

###### 

Comparison of Reaction time parameters between the Two study Groups after One Month

  **Group**                     **Sertraline + drug N = 14** **‎**   **Sertraline + placebo N = 16** **‎**   **P-value**
  ----------------------------- ------------------------------------ --------------------------------------- -------------
  Correct responses             8.43 ± 6.00                          9.69 ± 0.09                             0.663
  Substitution errors           10.57 ± 4.85                         8.19 ± 4.04                             0.153
  Omission errors               11.00 ± 5.94                         12.13 ± 7.90                            0.666
  Mean response time (second)   0.65 ± 0.12                          0.64 ± 0.12                             0.720
  Auditory test                 **mean ± SD**                        **mean ± SD**                           
  Correct responses             3.64 ± 1.69                          4.25 ± 3.51                             0.561
  Substitution errors           10.93 ± 5.84                         8.44 ± 4.94                             0.216
  Omission errors               15.43 ± 6.76                         17.31 ± 7.43                            0.476
  Mean response time (second)   0.49 ± 0.12                          0.55 ± 12                               0.467

\*: Significant difference (P-value \< 0.05)

SD: Standard deviation

###### 

Comparison of Reaction time parameters within each study group at baseline (1) and after One Month (2)

  Group                                                         **Sertraline + drug**   **P-value**                              **Sertraline + placebo**   **P-value**
  ------------------------------------------------------------- ----------------------- ---------------------------------------- -------------------------- -------------
  Correct responses [1](#TFN5){ref-type="table-fn"}             9.21 ± 7.99             0.555                                    10.69 ± 8.24               0.323
  Correct responses [2](#TFN6){ref-type="table-fn"}             8.43 ± 6.00                                                      9.69 ± 9.09                
  Substitution errors [1](#TFN5){ref-type="table-fn"}           9.14 ± 3.84             0.222                                    8.50 ± 4.82                0.808
  Substitution errors [2](#TFN6){ref-type="table-fn"}           10.57 ± 4.85                                                     8.19 ± 4.04                
  Omission errors [1](#TFN5){ref-type="table-fn"}               11.64 ± 6.79            0.585                                    10.81 ± 7.31               0.340
  Omission errors [2](#TFN6){ref-type="table-fn"}               11.00 ± 5.94                                                     12.13 ± 7.90               
  Mean response time [1](#TFN5){ref-type="table-fn"} (second)   0.59 ± 0.21             0.288                                    0.61 ± 0.21                0.549
  Mean response time [2](#TFN6){ref-type="table-fn"} (second)   0.64 ± 0.11                                                      0.64 ± 0.12                
  Auditory test                                                 **mean ± SD**                                                    **mean ± SD**              
  Correct responses [1](#TFN5){ref-type="table-fn"}             3.36 ± 1.45             0.537                                    4.19 ± 4.86                0.939
  Correct responses [2](#TFN6){ref-type="table-fn"}             3.64 ± 1.69                                                      4.25 ± 3.51                
  Substitution errors [1](#TFN5){ref-type="table-fn"}           8.71 ± 4.39             0.054                                    8.69 ± 4.76                0.845
  Substitution errors [2](#TFN6){ref-type="table-fn"}           10.93 ± 5.84                                                     8.44 ± 4.94                
  Omission errors [1](#TFN5){ref-type="table-fn"}               8.71 ± 4.39             0.045 [\*](#TFN3){ref-type="table-fn"}   17.13 ± 6.11               0.898
  Omission errors [2](#TFN6){ref-type="table-fn"}               15.43 ± 6.76                                                     17.31 ± 7.43               
  Mean response time [1](#TFN5){ref-type="table-fn"} (second)   0.44 ± 0.16             0.484                                    0.60 ± 0.16                0.312
  Mean response time [2](#TFN6){ref-type="table-fn"} (second)   0.49 ± 0.21                                                      0.54 ± 0.18                

: Significant difference (P-value \< 0.05)

SD: Standard deviation

: baseline

‎‎ : One month after drug or placebo consumption

###### 

Comparison of Hamilton Anxiety Rating Scale Form (HARS) at Baseline between the Two Study Groups

  Group           **Sertraline + drug N = 14**   **Sertraline + placebo N = 16**   **P-value**
  --------------- ------------------------------ --------------------------------- ----------------------------------------
  Baseline        21.54 ± 8.15                   24.07 ± 10.73                     0.495
  After 1 month   16.44 ± 7.15                   23.08 ± 8.85                      0.039 [\*](#TFN7){ref-type="table-fn"}

: Significant difference (P-value \< 0.05)

SD: Standard deviation

###### 

List of Reported Adverse Effects by Patients in Both Study Groups

  Group                    **Sertraline + drug**   **N = 14**   **Sertraline + placebo**   **N = 16**   **P-value**
  ------------------------ ----------------------- ------------ -------------------------- ------------ -------------
  Allergy                  **1**                   2.9 %        **1**                      2.9 %        0.925
  Asthma                   **1**                   2.9 %        **1**                      2.9 %        0.925
  Sinus irritation         **1**                   2.9 %        **1**                      2.9 %        0.925
  Dermatitis               **1**                   2.9 %        **3**                      **8.8%**     **0.634**
  Subcutaneous phlebitis   **0**                   **0%**       **0**                      **0%**       NS
  Tachycardia              **3**                   **8.8%**     **3**                      **8.8%**     0.861
  Nausea                   **7**                   **20.6%**    **3**                      **8.8%**     **0.319**
  Vomiting                 **2**                   **5.9%**     **0**                      **0%**       **0.165**
  Dizziness                **5**                   **14.7%**    **2**                      **5.9%**     0.155
  Somnolence               **8**                   **23.5%**    **7**                      **20.6%**    **0.481**
  Excessive sedation       **2**                   **5.9%**     **1**                      2.9 %        **0.493**
  Abnormal bleeding        **0**                   **0%**       **1**                      2.9 %        0.333
  etc.                     **3**                   **8.8%**     **4**                      **11.8%**    **0.825**

Fourteen patients (85.7% female and 14.3% male) were initiated on Sertraline (50 mg/day and ‎the dosage was increased to 100 mg/day after two weeks) + Pasipy (15 drops three times daily). ‎The mean age ± standard deviation (SD) of these patients was 29.07 ± 8.60. Sixteen patients ‎‎(87.5% female and 12.5% male) were initiated on Sertraline (50 mg/day and the dosage was ‎increased to 100 mg/day after two weeks) + placebo (15 drops three times daily). The mean age in ‎this group was 32.19 ± 11.43.‎

***Inter-group analysis***

After one month, independent sample t-test did not demonstrate any significant difference in any ‎of visual or auditory items. Baseline scores were proved not to be statistically different, but they ‎are not displayed in the tables. In the visual test for the drug group, the omission errors were less ‎than the placebo consumers, but this difference was not statistically significant (P = 0.666). ‎However, the mean reaction time was slightly longer in this group (P = 0.720).

‎In auditory analysis for the drug group, omission errors were less than the placebo group, but the ‎difference was not significant (P = 0.476). However, the mean reaction time toward sound threats ‎improved slightly after one month of taking Pasipy in the drug group compared to the placebo ‎group (P = 0.467) ([Table 2](#T2){ref-type="table"}).‎

***Intra-group Analysis***

In the drug group, a significant decline in auditory omission errors was observed after one month ‎of treatment (P = 0.045). The mean reaction time had a non-significant increase in both visual (P ‎‎= 0.288) and auditory tests (P = 0.484) in drug intra-group analysis. None of the changes in test ‎variables in placebo consumers reached the significant level. The mean reaction time was a bit ‎longer in the visual test (P = 0.549), but had a non-significant improvement toward auditory ‎ stimuli in this group (P = 0.312) ([Table 3](#T3){ref-type="table"}).

***Hamilton Test***

Hamilton Anxiety Rating Scale Form A (HARS) questionnaires were ranged between 18 to 24 (mild to moderate). A significant improvement to relieve anxiety symptoms was observed in the add-on therapy group compared to the Sertraline + placebo after one month of administration (P = 0.039) ([Table 4](#T4){ref-type="table"}).‎

***Adverse Reactions***

Based on data from [Table 5](#T5){ref-type="table"}, no major and significant adverse effect or drug interaction was observed after Sertraline + Pasipy co-administration compared to the other group. The most remarkable side effect in Sertraline + placebo group was somnolence (F = 7, percent = 20.6%), which occurred more frequently in add-on therapy (F = 8, percent = 23.5%).

Discussion
==========

'Fear appeal' is a brain message against threatening situations ([@B27]). It is a distinguishing ‎characteristic in anxiety disorders ([@B28]) which persuades the suffered patient to do a warily action. ‎This could explain reduced omission errors after add-on therapy. Therefore, passion flower seems ‎to increase the positive risky behavior and remove hesitance features as expected. It is ‎accompanied by the Hamilton test results that reconfirm the potential effects of this herbal ‎medicine for GAD. Slight and non-significant prolongation in mean response time (RT) is ‎explained by relieving pathological impulsiveness, which is one of the most distinguished features ‎of GAD ([@B29]). Numerous studies revealed that GAD rarely achieves high end-state functioning at ‎post-treatment, and the influence of these treatments on quality of life is not quite proved ([@B30]). ‎Pharmacotherapy has been claimed the main stage of treatment. Despite advantages, one of the ‎concerns about the first-line medication is cognitive side effects ([@B31], [@B32]). Among ‎Benzodiazepines, which are known as one of the most promising medications, the difficulty in ‎discontinuing these medications is a crucial dilemma ([@B1]). CBT has been believed to be the most ‎effective treatment in GAD among the non-pharmacological management. Studies that consider ‎CBT have some limitations; for instance, the inter-personal differences and long duration of such ‎experiments can restrict reaching confirmed conclusions ([@B33]). The pharmaceutical industry relies ‎on plant-based medicines significantly

([@B34]). ‎Passion flower and its active ingredients, chrysin and pyrone derivative maltol, are responsible for ‎the related CNS effects ([@B35]). Although the exact pharmacological mechanism is not fully known, ‎the majority of studies indicated that the sedative-hypnotic effects of passion flower are ‎presented through gama aminobutyric acid (GABA) neurotransmission ([@B36]). In a study by Appel ‎et al., passion flower was shown to antagonize GABAB receptor. However, ethanol site and ‎benzodiazepine site of GABAA receptors were not affected ([@B37]). Passion flower has been ‎demonstrated to be an efficacious drug for GAD management when compared with Oxazepam ‎and its undesirable side effects. The most preferences for anxiolytic effect of this phytotherapy ‎compared to the chemical medications are the venial impairment of performance ([@B24]), lack of ‎psychomotor dysfunction ([@B38]) or high sedation ([@B39]), which are promising in comparison with ‎psychiatric drugs with many of cognitive side effects ([@B18], [@B19]). The effects of cognitive function ‎have been reported in the literature. For example, in a study by Dimpfel et al., mathematical ‎calculation, concentration and memory tests were performed to evaluate the effects of passion ‎flower dry extract in a group of volunteers. The results showed no cognitive impairment even ‎though the psychometric scales were different from the RT test used in our study ([@B40]). Passion ‎flower 500 mg was administered before surgery and numerical rating scale (NRS) was utilized to ‎assess anxiety and sedation; besides, Trieger Dot Test and the Digit-Symbol Substitution were ‎used to evaluate psychomotor changes. The outcomes showed no significant difference in the ‎psychomotor function between the two groups after anesthesia ([@B41]). This study concluded that ‎passion flower does not affect reaction time, and therefore can be given to those patients whose ‎level of consciousness and speed of performance is important in their professional activities. In ‎our last trial, we found no adverse effect of passion flower on alertness in the healthy volunteers ([@B25]). However, small sample size and time limitation restricted our experiment. ‎

Limitations
===========

The limitations of the present study were as following: Firstly, the sample size was relatively small. Secondly, one month may not be considered long enough to precisely evaluate the effects of Passion flower extract. Thirdly, \"structured interview\", a more precise mean of evaluation of the patients, was not utilized in this study.

Conclusion
==========

This study noted that passion flower might be consumed as a safe (low side effects) add-on in the treatment of generalized ‎anxiety disorder. Further studies with longer duration are recommended to ‎confirm the results of this study.
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